Trial Profile
An Investigator-Masked, Dose-Escalation Study to Determine the Safety, Tolerability, Pharmacokinetics, and Efficacy of OPA-6566 Ophthalmic Solution in Subjects With Primary Open-Angle Glaucoma or Ocular Hypertension
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 01 Jul 2020
Price :
$35
*
At a glance
- Drugs OPA 6566 (Primary) ; Latanoprost
- Indications Ocular hypertension; Open-angle glaucoma
- Focus Adverse reactions
- Sponsors Acucela; Kubota Vision
- 20 Feb 2020 According to an Acucela media release, the company has changed its name to Kubota Vision, effective from 1 Apr 2020.
- 28 Apr 2014 New trial record